Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cytek Biosciences's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $385.5 Mil. Cytek Biosciences's Total Assets for the quarter that ended in Sep. 2024 was $491.2 Mil.
Therefore, Cytek Biosciences's Equity to Asset Ratio for the quarter that ended in Sep. 2024 was 0.79.
The historical rank and industry rank for Cytek Biosciences's Equity-to-Asset or its related term are showing as below:
CTKB'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.59 Med: 0.8 Max: 0.89
Current: 0.79
During the past 5 years, the highest Equity to Asset Ratio of Cytek Biosciences was 0.89. The lowest was -0.59. And the median was 0.80.
CTKB's Equity-to-Asset is ranked better than 73.85% of 868
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs CTKB: 0.79
Cytek Biosciences Equity-to-Asset Historical Data
The historical data trend for Cytek Biosciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cytek Biosciences's Equity-to-Asset
For the Medical Devices subindustry, Cytek Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's Equity-to-Asset falls into.
Cytek Biosciences Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Cytek Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Cytek Biosciences Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Cytek Biosciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CTKB has been successfully added to your 